Therapy of Alzheimer's dementia: Status quo and future perspectives;Therapie der Alzheimer-demenz: Status quo und zukunftsperspektiven

Journal fur Neurologie, Neurochirurgie und Psychiatrie

Volumn 11, Issue 4, 2010, Pages 72-78

  Moser, Ulrike ^a   Kasper, S ^a   Winkler, D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alzheimer's dementia; Dementia; Treatment

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; COGNITION; DEGENERATIVE DISEASE; HUMAN; LIFE EXPECTANCY; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 78649493134     PISSN: 16081587     EISSN: 16809440     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Österreichische Alzheimer Liga. Available from: http://www. alzheimer-liga.at/aufgaben.html [gesehen 4.12.2008].
2. Reisberg B, Prichep L, Mosconi L, John ER, Glodzik-Sobanska L, Boksay I, Monteiro I, Torossian C, Vedvyas A, Ashraf N, Jamil IA, de Leon MJ. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement 2008; 4 (Suppl 1): S98-S108.
3. National Institute on Aging. The Seven Warning Signs of Alzheimer's Disease. http://www.nia.nih.gov/Alzheimers/Publications/sevensigns.htm [gesehen 4.12.2008].
4. Hellweg R. Demenzerkrankungen. In: Gastpar MT, Kasper S, Linden M (Hrsg). Psychiatrie und Psychotherapie. Springer-Verlag, Wien-New York, 2003; 37-44.
5. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-78.
6. Bird TD. Genetic aspects of Alzheimer disease. Genet Med 2008; 10: 231-9.
7. Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol 2008; 8: 9.
8. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007; 11: 1227-38.
9. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994; 264: 1336-40.
10. Yankner BA, Lu T. Amyloid beta -protein toxicity and the pathogenesis of Alzheimer's disease. J Biol Chem 2009; 284: 4755-9.
11. Alonso AC, Li B, Grundke-Iqbal I, Iqbal K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2008; 5: 375-84.
12. Frolich L. The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002; 109: 1003-13.
13. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 342-5.
14. Bianchetti A, Ranieri P, Margiotta A, Trabucchi M. Pharmacological treatment of Alzheimer's Disease. Aging Clin Exp Res 2006; 18: 158-62.
15. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008; 24: 157-66.
16. Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999; 45 (Suppl 1): 23-32.
17. Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007; 8: 1011-23.
18. Fuchs GA, Gemende I, Herting B, Lemke MR, Oehlwein C, Reichmann H, Rieke J, Emmans D, Volkmann J. Dementia in idiopathic Parkinson's syndrome. J Neurol 2004; 251 (Suppl 6): VI/28-VI/32.
19. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9: 101-24.
20. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002; 14 (Suppl 1): 77-91.
21. Roman GC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurother 2005; 5: 309-13.
22. Rozzini L, Chilovi BV, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padovani A. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. Am J Alzheimers Dis Other Demen 2007; 22: 42-7.
23. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2001; (4): CD001747.
24. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69: 448-58.
25. Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis 2008; 14: 193-9.
26. Molinuevo JL, Garcia-Gil V, Villar A. Memantine: an antiglutamatergic option for dementia. Am J Alzheimers Dis Other Demen 2004; 19: 10-8.
27. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-21.
28. Starkstein SE, Mizrahi R, Power BD. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatry 2008; 20: 382-8.
29. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43.
30. Savaskan E, Schnitzler C, Schroder C, Cajochen C, Müller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol 2006; 9: 507-16.
31. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91-103.
32. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
33. Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, Trabucchi M. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. Alzheimer Dis Assoc Disord 2008; 22: 158-62.
34. Dowling GA, Graf CL, Hubbard EM, Luxenberg JS. Light treatment for neuropsychiatric behaviors in Alzheimer's disease. West J Nurs Res 2007; 29: 961-75.
35. Acevedo A, Loewenstein DA. Nonpharmacological cognitive interventions in aging and dementia. J Geriatr Psychiatry Neurol 2007; 20: 239-49.
36. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008; 4: 65-79.
37. Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008; 7: 805-11.
38. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-62.
39. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792- associated meningoencephalitis. Neurodegener Dis 2008; 5: 194-6.
40. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Longterm effects of Aβ 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-23.
41. Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opin Biol Ther 2008; 8: 633-42.
42. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15: 157-68.
43. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-29.
44. Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008; 5: 391-8.
45. Siemers ER, Dean RA, Friedrich S, Ferguson- Sells L, Gonzales C, Farlow MR, May PC. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007; 30: 317-25.
46. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-8.
47. Wright TM. Tramiprosate. Drugs Today (Barc) 2006; 42: 291-8.
48. Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L, Gandy SE, Rovner B, Fitzsimmons BF, Smith EE, Edip Gurol M, Schwab K, Laurin J, Garceau D. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 2006; 20: 269-74.
49. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-91.
50. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14: 973-8.
51. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: 225-36.
52. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008; 70: 17-24.
53. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199: 265-73.
54. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-80.
55. Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009; 202: 53-65.
56. Friess E, Schiffelholz T, Steckler T, Steiger A. Dehydroepiandrosterone - a neurosteroid. Eur J Clin Invest 2000; 30 (Suppl 3): 46-50.
57. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 300-3.
58. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 2006; 1762: 447-52.
59. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 300-3.
60. Dhikav V, Anand KS. Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486). Med Hypotheses 2007; 68: 1088-92.
61. Pomara N, Doraiswamy PM, Tun H, Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002; 58: 1436.
62. Schechter LE, Smith DL, Rosenzweig- Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005; 314: 1274-89.
63. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939: 425-35.
64. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-15.
65. Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs 2008; 17: 209-15.